 Pyridines
"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 | | 1999 | 1 | 2 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 3 | 5 | 8 | | 2002 | 2 | 5 | 7 | | 2003 | 2 | 4 | 6 | | 2004 | 3 | 6 | 9 | | 2005 | 0 | 2 | 2 | | 2006 | 6 | 2 | 8 | | 2007 | 6 | 4 | 10 | | 2008 | 5 | 3 | 8 | | 2009 | 13 | 2 | 15 | | 2010 | 8 | 10 | 18 | | 2011 | 10 | 9 | 19 | | 2012 | 12 | 15 | 27 | | 2013 | 22 | 12 | 34 | | 2014 | 14 | 10 | 24 | | 2015 | 12 | 8 | 20 | | 2016 | 17 | 11 | 28 | | 2017 | 11 | 5 | 16 | | 2018 | 9 | 5 | 14 | | 2019 | 10 | 4 | 14 | | 2020 | 3 | 5 | 8 | | 2021 | 9 | 13 | 22 | | 2022 | 2 | 16 | 18 | | 2023 | 0 | 20 | 20 | | 2024 | 11 | 6 | 17 | | 2025 | 12 | 11 | 23 | | 2026 | 9 | 12 | 21 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Stacchiotti S, Blay JY, Rutkowski P, Gelderblom H, Falcón A, Le Cesne A, Desai J, Palmerini E, Serrano C, Ganjoo KN, D'Amato GZ, Ryan CW, Wilky BA, Ferraresi V, Saleh R, Ravi V, Razak AA, Herráez AC, Ahmed M, Bernthal NM, van de Sande M, Brahmi M, Szostakowski B, Sen J, Zeringo NA, Harrow B, Narasimhan S, Saunders A, Sharma MG, Sherman ML, Wagner AJ, Tap WD. Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial. Cancer. 2026 Sep 01; 132(17):e70564.
-
Paris V, Buultjens AH, Bell N, Schmidt TL, Bamberg WM, Birrell MT, Romanes F, Antao CA, Globan M, Lavender C, Bond K, Dougall S, Lacey JA, Zhai Y, Guo P, Sherry NL, Gibney KB, Lim JT, Johnson PDR, Stinear TP, Hoffmann AA. Autodissemination stations suppress Aedes notoscriptus mosquitoes and reduce Buruli ulcer risk in urban Australia: a randomized controlled field trial. Nat Microbiol. 2026 Sep; 11(9):2493-2504.
-
Duncan CL, von Isenburg M, Green A, Ford C, Pucci A, Muther EF, Riekert KA, Bord E, Hoppe JE, Bacon C, Goodman A, Lyons E, Prickett M, Gibson SL, Everhart RS. Caregiver Mental Health and Its Relation to Child and Adolescent Mental and Behavioral Health in the Era of Highly Effective Modulator Therapy for Cystic Fibrosis. Pediatr Pulmonol. 2026 Aug; 61(8):e71794.
-
Da Cruz RS, Teague HL, Ramos-Benitez MJ, Malavez-Cajigas SJ, Williams T, Miao R, Tian X, Lin G, Busse LW, Khan A, Moskowitz A, Hager DN, Rice TW, Ginde AA, Iovine NM, Chen P, Safdar B, Gibbs KW, Javaheri A, de Wit M, Harkins M, Hudock K, Merck LH, Barksdale A, Sturek JM, Schrager H, Shapiro NI, Lanspa M, Harris E, Sellers S, Goodwin AJ, Tidswell MA, Filbin MR, Shotwell MS, Semler MW, Self WH, Collins SP, Strich JR. Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
-
Chalamalla AR, Baker E, Ryan KJ, Dowell A, Natt JR, Zemanick ET, Konstan MW, Mayer-Hamblett N, Acosta EP, Guimbellot JS. Impact of CFTR modulator concentrations on clinical response in cystic fibrosis. Eur Respir J. 2026 Jun; 67(6).
-
Muther EF, Gibson SL, Ford C, Duncan C, Riekert KA, Lyons E, Hoppe JE, Prickett M, Isenburg MV, Everhart RS. People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor. Respir Med. 2026 Aug; 259:108908.
-
Downey DG, Houston C, Mayer-Hamblett N, Taylor-Cousar JL, Taggart CC. Contributors to the heterogeneity of response to CFTR modulators. Lancet Respir Med. 2026 Aug; 14(8):717-729.
-
Piarowski CM, Scott JK, Wilson CE, Lara HI, Salcedo E, Han AS, Lam ET, Dempsey PJ, von Moltke J, Barlow LA. Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition. Development. 2026 04 15; 153(8).
-
Wen PY, Berry DA, Buxton MB, Colman H, de Groot J, Lim M, Mellinghoff I, Perry JR, Weller M, Blondin NA, Butt OH, Damek DM, de la Fuente MI, Drappatz J, Dunbar E, Giglio P, Hyddmark EV, Iwamoto F, Jaeckle KA, Kim L, Kling HM, Lee EQ, Mantica M, Mikkelsen T, Nabors B, Newton HB, Olson JJ, Schiff D, Walbert T, Weathers SP, Cloughesy T, Lassman AB. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026 06 20; 44(18):1676-1686.
-
Wyles DL, Matsuda K, Iwaki Y, Klonowski E. Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study. BMC Pulm Med. 2026 Apr 02; 26(1).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|